Navigate: a study protocol for a randomised controlled trial of an online treatment decision aid for men with low-risk prostate cancer and their partners

被引：0
作者：
Penelope Schofield
Karla Gough
Amelia Hyatt
Alan White
Mark Frydenberg
Suzanne Chambers
Louisa G. Gordon
Robert Gardiner
Declan G. Murphy
Lawrence Cavedon
Natalie Richards
Barbara Murphy
Stephen Quinn
Ilona Juraskova
机构：
[1] Swinburne University of Technology,Department of Psychology
[2] Peter MacCallum Cancer Centre,Behavioural Science Unit
[3] The University of Melbourne,Sir Peter MacCallum Department of Oncology
[4] Swinburne University of Technology,Department of Nursing
[5] The University of Melbourne,Department of Urology
[6] Cabrini Institute,Department of Surgery
[7] Cabrini Health,Faculty of Health
[8] Monash University,Health and Wellness Institute
[9] University of Technology Sydney,Institute for Resilient Regions
[10] Edith Cowan University,Menzies Health Institute Queensland
[11] University of Southern Queensland,Population Health Department, Health Economics
[12] Griffith University,School of Nursing
[13] QIMR Berghofer Medical Research Institute,School of Public Health
[14] Queensland University of Technology (QUT),School of Medicine
[15] University of Queensland,Department of Urology
[16] University of Queensland,Division of Cancer Surgery
[17] Royal Brisbane & Women’s Hospital,School of Science
[18] Peter MacCallum Cancer Centre,Department of Psychology
[19] RMIT University,Faculty of Health
[20] The University of Melbourne,Department of Health Science and Biostatistics
[21] Deakin University,School of Psychology, Faculty of Science, Centre for Medical Psychology and Evidence
[22] Swinburne University of Technology,based Decision
[23] University of Sydney,making (CeMPED)
来源：
Trials | / 22卷
关键词：
Low-risk prostate cancer; Decision aid; Management decision; Treatment decision; Active surveillance; RCT; Distress; Quality of life;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 168 条
[1]  
Ferlay J(2015)Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 Int J Cancer 136 E359-EE86
[2]  
Soerjomataram I(2017)The impact of the United States Preventive Services Task Force (USPTSTF) recommendations against prostate-specific antigen (PSA) testing on PSA testing in Australia BJU Int 119 10-115
[3]  
Dikshit R(2018)Patterns of care and outcomes for men diagnosed with prostate cancer in Victoria: an update ANZ J Surg 88 1037-1042
[4]  
Zargar H(2010)Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to PSA-screening Cancer Epidemiol Biomark Prev 19 1201-1207
[5]  
van den Bergh R(2017)‘ProtecTion’ from overtreatment: does a randomized trial finally answer the key quesiton in localized prostate cancer? BJU Int 119 513-514
[6]  
Moon D(2016)10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer N Engl J Med 375 1415-1424
[7]  
Lawrentschuk N(2017)Long-term follow-up after active surveillance or curative treatment: quality-of-life outcomes of men with low-risk prostate cancer Qual Life Res 26 1635-1645
[8]  
Costello A(2016)Longitudinal assessment of quality of life after surgery, conformal brachytherapy, and intensity-modulated radiation therapy for prostate cancer Radiother Oncol 118 85-91
[9]  
Murphy D(2010)Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment Eur Urol 58 831-835
[10]  
Wang LL(2018)Active surveillance for low-risk prostate cancer: the European Association of Urology Position in 2018 Eur Urol 74 357-368
12345678910